News from Uppsala Health Summit
August 2017
 
The story of a successful partnership
 
In December last year, an article in The Lancet and a press communiqué from the WHO affirmed that the long journey towards and efficacious vaccine against the Zaïre Ebola virus (ZEBOV) was coming to a close. Clinical trials in Guinea confirmed that the vaccine was safe and offered efficient protection against the Zaïre Ebola Virus.
 
Article Image
The promising results make it probable that we will soon have a tested, safe and efficacious vaccine against Zaire Ebola virus on the market.
 
This is a short recapitulation of how global collaboration between scientists, field workers and experts from academia, public health authorities, regulatory bodies, NGOs and industry developed promising laboratory work into a prophylactic vaccine, and of the benefits of collaboration over global and administrative borders.
 

 
Meet Dr Beth-Ann Coller, Ebola Vaccine Director at Merck & Co Inc.
 
Dr Coller
– Successful clinical trials carried out in the midst of an epidemic and the fact that we soon hope to be able to provide an efficacious prophylactic vaccine against Ebola Zaire, is the result of the collaboration between a number of highly experienced partners says Dr. Beth-Ann Coller, Executive Director with Merck & Co.,where she leads the product development of vaccines against Ebola and other zoonotic diseases. Dr Coller is one of the keynote speakers at Uppsala Health Summit in October.
 
In this article, Dr. Beth-Ann Coller describes the role played by Merck in this process and the experiences gained along the way.

 
Meet Dr. Christianne Bruschke, the Netherlands’ Chief Veterinary Officer in an interview
 
Article Image
In 2007, the Netherlands started to detect cases of Q-fever in humans.The disease which is caused by Coxiella bunetii bacteria, can trigger abortions in sheep, goats and cows, but can lead to pneumonia in humans. After over 2000 confirmed human cases of Q-fever, the Dutch authorities took the rather controversial decision to cull over 50 000 dairy goats, that had been identified as the source of the infection.
 
The Netherlands’ Chief Veterinary Officer, Dr. Christianne Bruschke, has on many occasions explained why this tough decision was necessary. Dr. Bruschke is one of the keynote speakers at Uppsala Health Summit in October, where she will share the Dutch experiences of responding to an outbreak of a zoonosis in one of the world’s most densely populated countries and the world’s second largest exporter of dairy products.
 
 
 
Share your Thinking in Social Media
 
Article Image We need to share thinking on how to improve health and healthcare globally.
 
For quick comments and updates on healthpolicy news, we suggest you to follow our Twitter account. We will follow you back to make sure we don't miss any of your updates.
 
In Uppsala Health Summit's LinkedIn group we share articles that we come across that we believe is of interest to you all. Join the group to share your news and comment on others!
 

 
 
UHS Partners
 
Article Image
 

Would you like to forward this email to a friend? Click here.

Share This Email: Facebook   Twitter   Digg   Linked In  
Remove my name from all future mass email communications.

Address postal inquiries to:
Uppsala University
P.O. Box 256
Uppsala
751 05